Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

TNF-alpha and pathologic bone resorption.

Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, Schwarz EM, O'Keefe RJ, Xing L.

Keio J Med. 2005 Sep;54(3):127-31. Review.

2.

Role of cytokines in bone resorption.

Manolagas SC.

Bone. 1995 Aug;17(2 Suppl):63S-67S. Review.

PMID:
8579900
3.

Mechanisms of bone resorption and new bone formation in spondyloarthropathies.

Huang W, Schwarz EM.

Curr Rheumatol Rep. 2002 Dec;4(6):513-7. Review.

PMID:
12427367
4.

Bone loss in inflammatory arthritis: mechanisms and treatment strategies.

Walsh NC, Gravallese EM.

Curr Opin Rheumatol. 2004 Jul;16(4):419-27. Review.

PMID:
15201606
5.

Rheumatic diseases: the effects of inflammation on bone.

Walsh NC, Crotti TN, Goldring SR, Gravallese EM.

Immunol Rev. 2005 Dec;208:228-51. Review.

PMID:
16313352
6.

Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.

Romas E.

Best Pract Res Clin Rheumatol. 2005 Dec;19(6):1065-79. Review.

PMID:
16301197
7.

Osteoclastogenesis and arthritis.

Maruotti N, Grano M, Colucci S, d'Onofrio F, Cantatore FP.

Clin Exp Med. 2011 Sep;11(3):137-45. doi: 10.1007/s10238-010-0117-2. Epub 2010 Nov 11. Review.

PMID:
21069419
8.

RANKL-RANK signaling in osteoclastogenesis and bone disease.

Wada T, Nakashima T, Hiroshi N, Penninger JM.

Trends Mol Med. 2006 Jan;12(1):17-25. Epub 2005 Dec 13. Review.

PMID:
16356770
9.

Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.

Anandarajah AP, Schwarz EM.

J Cell Biochem. 2006 Feb 1;97(2):226-32. Review.

PMID:
16240334
10.

Human osteoclast ontogeny and pathological bone resorption.

Athanasou NA, Sabokbar A.

Histol Histopathol. 1999 Apr;14(2):635-47. Review.

PMID:
10212824
11.

Pathogenesis of bone and cartilage destruction in rheumatoid arthritis.

Goldring SR.

Rheumatology (Oxford). 2003 May;42 Suppl 2:ii11-6. Review.

12.

Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.

Tanaka S.

Am J Nephrol. 2007;27(5):466-78. Epub 2007 Jul 25. Review. Erratum in: Am J Nephrol. 2007;27(5):544.

PMID:
17652963
13.

The molecular understanding of osteoclast differentiation.

Asagiri M, Takayanagi H.

Bone. 2007 Feb;40(2):251-64. Epub 2006 Nov 13. Review.

PMID:
17098490
14.

[Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis--new therapeutical opportunities].

Kmieć Z, Sokołowska I.

Pol Merkur Lekarski. 2007 Apr;22(130):300-4. Review. Polish.

PMID:
17684931
15.

Osteoclastogenesis and osteoclast activation in dialysis-related amyloid osteopathy.

Kazama JJ, Maruyama H, Gejyo F.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S156-60. Review.

PMID:
11576944
16.

The role of tumor necrosis factor-alpha (TNF-alpha) in bone resorption present in middle ear cholesteatoma.

Vitale RF, Ribeiro Fde A.

Braz J Otorhinolaryngol. 2007 Jan-Feb;73(1):117-21. Review.

17.

Osteoclast precursors, RANKL/RANK, and immunology.

Xing L, Schwarz EM, Boyce BF.

Immunol Rev. 2005 Dec;208:19-29. Review.

PMID:
16313338
18.

Mechanisms of Disease: the link between RANKL and arthritic bone disease.

Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS.

Nat Clin Pract Rheumatol. 2005 Nov;1(1):47-54. Review.

PMID:
16932627
19.

Osteoclasts, rheumatoid arthritis, and osteoimmunology.

Sato K, Takayanagi H.

Curr Opin Rheumatol. 2006 Jul;18(4):419-26. Review.

PMID:
16763464
20.

Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention.

Karmakar S, Kay J, Gravallese EM.

Rheum Dis Clin North Am. 2010 May;36(2):385-404. doi: 10.1016/j.rdc.2010.03.003. Review.

Items per page

Supplemental Content

Write to the Help Desk